Tango Therapeutics, Inc.
NGM: TNGXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Tango Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TNGX Z-Score →About Tango Therapeutics, Inc.
Healthcare
Biotechnology
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Tango Therapeutics, Inc. demonstrates a profit margin of -162.9%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -37.2%, which indicates that capital utilization is currently under pressure.
At a current price of $19.95, TNGX currently trades near the top of its 52-week range (89%) (Range: $1.03 - $22.20).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$2.85B
Trailing P/E
--
Forward P/E
-12.52
Beta (5Y)
1.31
52W High
$22.20
52W Low
$1.03
Avg Volume
3.30M
Day High
Day Low